Translating promising preclinical neuroprotective therapies to human stroke trials

References

• Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation121(7), e46–e215 (2010).
   PubMed Web of Science ®Google Scholar
• Zorowitz RD, Chen E, Tong KB, Laouri M. Costs and rehabilitation use of stroke survivors: a retrospective study of Medicare beneficiaries. Top Stroke Rehabil.16(5), 309–320 (2009).
   PubMed Web of Science ®Google Scholar
• Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th Century. Stroke32(6), 1349–1359 (2001).
   PubMed Web of Science ®Google Scholar
• Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke33(8), 2123–2136 (2002).
   PubMed Web of Science ®Google Scholar
• O’Collins VE, Macleod MR, Donnan GA, Horky LL, van Der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann. Neurol.59(3), 467–477 (2006).
   PubMed Web of Science ®Google Scholar
• Carmichael ST. Rodent models of focal stroke: size, mechanism, and purpose. NeuroRx2(3), 396–409 (2005).
   PubMedGoogle Scholar
• Fisher M, Finklestein S. Pharmacological approaches to stroke recovery. Cerebrovasc. Dis.9(Suppl. 5), 29–32 (1999).
   PubMedGoogle Scholar
• Howells DW, Porritt MJ, Rewell SS et al. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J. Cereb. Blood Flow Metab.30(8), 1412–1431 (2010).
   PubMed Web of Science ®Google Scholar
• Macleod MR, O’collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke35(5), 1203–1208 (2004).
   PubMed Web of Science ®Google Scholar
• STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke30(12), 2752–2758 (1999).
   PubMed Web of Science ®Google Scholar
• Fisher M, Feuerstein G, Howells DW et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke40(6), 2244–2250 (2009).
   PubMed Web of Science ®Google Scholar
• Maples KR, Green AR, Floyd RA. Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. CNS Drugs18(15), 1071–1084 (2004).
   PubMed Web of Science ®Google Scholar
• Hess DC. NXY-059: a hopeful sign in the treatment of stroke. Stroke37(10), 2649–2650 (2006).
   PubMedGoogle Scholar
• Marshall JW, Ridley RM. Assessment of cognitive and motor deficits in a marmoset model of stroke. ILAR J.44(2), 153–160 (2003).
   PubMedGoogle Scholar
• Marshall JW, Ridley RM, Baker HF, Hall LD, Carpenter TA, Wood NI. Serial MRI, functional recovery, and long-term infarct maturation in a non-human primate model of stroke. Brain Res. Bull.61(6), 577–585 (2003).
   PubMedGoogle Scholar
• Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical – trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke32(1), 190–198 (2001).
   PubMed Web of Science ®Google Scholar
• Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke34(9), 2228–2233 (2003).
   PubMed Web of Science ®Google Scholar
• Marshall JW, Green AR, Ridley RM. Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. Brain Res.972(1–2), 119–126 (2003).
   PubMed Web of Science ®Google Scholar
• Lees KR, Zivin JA, Ashwood T et al. NXY-059 for acute ischemic stroke. N. Engl. J. Med.354(6), 588–600 (2006).
   PubMed Web of Science ®Google Scholar
• Shuaib A, Lees KR, Lyden P et al. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med.357(6), 562–571 (2007).
   PubMed Web of Science ®Google Scholar
• Diener HC, Lees KR, Lyden P et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke39(6), 1751–1758 (2008).
   PubMed Web of Science ®Google Scholar
• Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab.26(12), 1465–1478 (2006).
   PubMed Web of Science ®Google Scholar
• Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann. Neurol.61(5), 396–402 (2007).
   PubMed Web of Science ®Google Scholar
• Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in Phase II/III acute ischemic stroke trials. Stroke40(2), 577–581 (2009).
   PubMed Web of Science ®Google Scholar
• Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp. Neurol.205(1), 20–25 (2007).
   PubMed Web of Science ®Google Scholar
• Liu Y, Song XD, Liu W, Zhang TY, Zuo J. Glucose deprivation induces mitochondrial dysfunction and oxidative stress in PC12 cell line. J. Cell Mol. Med.7(1), 49–56 (2003).
   PubMedGoogle Scholar
• Behl C, Lezoualc’h F, Trapp T, Widmann M, Skutella T, Holsboer F. Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology138(1), 101–106 (1997).
   PubMed Web of Science ®Google Scholar
• Booher J, Sensenbrenner M. Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology2(3), 97–105 (1972).
   PubMedGoogle Scholar
• Goldberg MP, Choi DW. Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. J. Neurosci.13(8), 3510–3524 (1993).
   PubMed Web of Science ®Google Scholar
• Newell DW, Barth A, Papermaster V, Malouf AT. Glutamate and non-glutamate receptor mediated toxicity caused by oxygen and glucose deprivation in organotypic hippocampal cultures. J. Neurosci.15(11), 7702–7711 (1995).
   PubMed Web of Science ®Google Scholar
• Strasser U, Fischer G. Quantitative measurement of neuronal degeneration in organotypic hippocampal cultures after combined oxygen/glucose deprivation. J. Neurosci. Methods57(2), 177–186 (1995).
   PubMed Web of Science ®Google Scholar
• Taylor CP, Weber ML, Gaughan CL, Lehning EJ, Lopachin RM. Oxygen/glucose deprivation in hippocampal slices: altered intraneuronal elemental composition predicts structural and functional damage. J. Neurosci.19(2), 619–629 (1999).
   PubMed Web of Science ®Google Scholar
• Bacigaluppi M, Comi G, Hermann DM. Animal models of ischemic stroke. Part two: modeling cerebral ischemia. Open Neurol. J.4, 34–38 (2010).
   PubMedGoogle Scholar
• Sundstrom L, Morrison B 3rd, Bradley M, Pringle A. Organotypic cultures as tools for functional screening in the CNS. Drug Discov. Today10(14), 993–1000 (2005).
   PubMed Web of Science ®Google Scholar
• Feuerstein GZ, Chavez J. Translational medicine for stroke drug discovery: the pharmaceutical industry perspective. Stroke40(Suppl. 3), S121–S125 (2009).
   PubMed Web of Science ®Google Scholar
• Mattson MP, Barger SW, Begley JG, Mark RJ. Calcium, free radicals, and excitotoxic neuronal death in primary cell culture. Methods Cell Biol.46, 187–216 (1995).
   PubMed Web of Science ®Google Scholar
• Li L, Prabhakaran K, Shou Y, Borowitz JL, Isom GE. Oxidative stress and cyclooxygenase-2 induction mediate cyanide-induced apoptosis of cortical cells. Toxicol. Appl. Pharmacol.185(1), 55–63 (2002).
   PubMedGoogle Scholar
• Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch.460(2), 525–542 (2010).
   PubMed Web of Science ®Google Scholar
• Szydlowska K, Tymianski M. Calcium, ischemia and excitotoxicity. Cell Calcium47(2), 122–129 (2010).
   PubMed Web of Science ®Google Scholar
• Choi DW, Maulucci-Gedde M, Kriegstein AR. Glutamate neurotoxicity in cortical cell culture. J. Neurosci.7(2), 357–368 (1987).
   PubMed Web of Science ®Google Scholar
• Rose CR, Ransom BR. Mechanisms of H+ and Na+ changes induced by glutamate, kainate, and D-aspartate in rat hippocampal astrocytes. J. Neurosci.16(17), 5393–5404 (1996).
   PubMedGoogle Scholar
• Jensen JB, Schousboe A, Pickering DS. AMPA receptor mediated excitotoxicity in neocortical neurons is developmentally regulated and dependent upon receptor desensitization. Neurochem. Int.32(5–6), 505–513 (1998).
   PubMedGoogle Scholar
• Lau AC, Cui H, Tymianski M. The use of propidium iodide to assess excitotoxic neuronal death in primary mixed cortical cultures. Methods Mol. Biol.399, 15–29 (2007).
   PubMedGoogle Scholar
• Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction J. Neurochem.69(2), 581–593 (1997).
   PubMed Web of Science ®Google Scholar
• Greene LA, Aletta JM, Rukenstein A, Green SH. PC12 pheochromocytoma cells: culture, nerve growth factor treatment, and experimental exploitation. Methods Enzymol.147, 207–216 (1987).
   PubMed Web of Science ®Google Scholar
• Choi DW. Ischemia-induced neuronal apoptosis. Curr. Opin. Neurobiol.6(5), 667–672 (1996).
   PubMed Web of Science ®Google Scholar
• Dugan LL, Sensi SL, Canzoniero LM et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J. Neurosci.15(10), 6377–6388 (1995).
   PubMed Web of Science ®Google Scholar
• Lee WH, Kang S, Vlachos PP, Lee YW. A novel in vitro ischemia/reperfusion injury model. Arch. Pharm. Res.32(3), 421–429 (2009).
   PubMedGoogle Scholar
• Lok J, Gupta P, Guo S et al. Cell–cell signaling in the neurovascular unit. Neurochem. Res.32(12), 2032–2045 (2007).
   PubMed Web of Science ®Google Scholar
• Grant GA, Abbott NJ, Janigro D. Understanding the physiology of the blood-brain barrier: in vitro models. News Physiol. Sci.13, 287–293 (1998).
   PubMedGoogle Scholar
• Balbuena P, Li W, Magnin-Bissel G, Meldrum JB, Ehrich M. Comparison of two blood–brain barrier in vitro systems: cytotoxicity and transfer assessments of malathion/oxon and lead acetate. Toxicol. Sci.114(2), 260–271 (2010).
   PubMedGoogle Scholar
• Holopainen IE. Organotypic hippocampal slice cultures: a model system to study basic cellular and molecular mechanisms of neuronal cell death, neuroprotection, and synaptic plasticity. Neurochem. Res.30(12), 1521–1528 (2005).
   PubMed Web of Science ®Google Scholar
• Noraberg J, Poulsen FR, Blaabjerg M et al. Organotypic hippocampal slice cultures for studies of brain damage, neuroprotection and neurorepair. Curr. Drug Targets CNS Neurol. Disord.4(4), 435–452 (2005).
   PubMedGoogle Scholar
• Yakovlev AG, Faden AI. Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRx1(1), 5–16 (2004).
   PubMedGoogle Scholar
• Sapolsky RM. Neuroprotective gene therapy against acute neurological insults. Nat. Rev. Neurosci.4(1), 61–69 (2003).
   PubMed Web of Science ®Google Scholar
• Stieger K, Belbellaa B, Le Guiner C, Moullier P, Rolling F. In vivo gene regulation using tetracycline-regulatable systems. Adv. Drug Deliv. Rev.61(7–8), 527–541 (2009).
   PubMed Web of Science ®Google Scholar
• Cui H, Hayashi A, Sun HS et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J. Neurosci.27(37), 9901–9915 (2007).
   PubMed Web of Science ®Google Scholar
• Culmsee C, Krieglstein J. Ischaemic brain damage after stroke: new insights into efficient therapeutic strategies. International Symposium on Neurodegeneration and Neuroprotection. EMBO Rep.8(2), 129–133 (2007).
   PubMedGoogle Scholar
• Sattler R, Xiong Z, Lu WY, Hafner M, Macdonald JF, Tymianski M. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science284(5421), 1845–1848 (1999).
   PubMed Web of Science ®Google Scholar
• Aarts M, Liu Y, Liu L et al. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science298(5594), 846–850 (2002).
   PubMed Web of Science ®Google Scholar
• Braeuninger S, Kleinschnitz C. Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems. Exp. Transl. Stroke Med.1, 8 (2009).
   PubMedGoogle Scholar
• Jonas S, Aiyagari V, Vieira D, Figueroa M. The failure of neuronal protective agents versus the success of thrombolysis in the treatment of ischemic stroke. The predictive value of animal models. Ann. NY Acad. Sci.939, 257–267 (2001).
   PubMedGoogle Scholar
• Cramer SC. Clinical issues in animal models of stroke and rehabilitation. ILAR J.44(2), 83–84 (2003).
   PubMedGoogle Scholar
• Hunter AJ, Green AR, Cross AJ. Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? Trends Pharmacol. Sci.16(4), 123–128 (1995).
   PubMed Web of Science ®Google Scholar
• Curry SH. Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships. Ann. NY Acad. Sci.993, 69–74; discussion 79–81 (2003).
   PubMed Web of Science ®Google Scholar
• Bacigaluppi M, Comi G, Hermann DM. Animal models of ischemic stroke. Part one: modeling risk factors. Open Neurol. J.4, 26–33 (2010).
   PubMedGoogle Scholar
• Hoyte L, Kaur J, Buchan AM. Lost in translation: taking neuroprotection from animal models to clinical trials. Exp. Neurol.188(2), 200–204 (2004).
   PubMed Web of Science ®Google Scholar
• Mergenthaler P, Dirnagl U, Meisel A. Pathophysiology of stroke: lessons from animal models. Metab. Brain Dis.19(3–4), 151–167 (2004).
   PubMed Web of Science ®Google Scholar
• Fukuda S, Del Zoppo GJ. Models of focal cerebral ischemia in the nonhuman primate. ILAR J.44(2), 96–104 (2003).
   PubMed Web of Science ®Google Scholar
• Bihel E, Pro-Sistiaga P, Letourneur A et al. Permanent or transient chronic ischemic stroke in the non-human primate: behavioral, neuroimaging, histological, and immunohistochemical investigations. J. Cereb. Blood Flow Metab.30(2), 273–285 (2010).
   PubMedGoogle Scholar
• Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke17(3), 472–476 (1986).
   PubMed Web of Science ®Google Scholar
• Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke20(1), 84–91 (1989).
   PubMed Web of Science ®Google Scholar
• Yanamoto H, Nagata I, Niitsu Y, Xue JH, Zhang Z, Kikuchi H. Evaluation of MCAO stroke models in normotensive rats: standardized neocortical infarction by the 3VO technique. Exp. Neurol.182(2), 261–274 (2003).
   PubMed Web of Science ®Google Scholar
• Peeling J, Corbett D, Del Bigio MR, Hudzik TJ, Campbell TM, Palmer GC. Rat middle cerebral artery occlusion: correlations between histopathology, T2-weighted magnetic resonance imaging, and behavioral indices. J. Stroke Cerebrovasc. Dis.10(4), 166–177 (2001).
   PubMedGoogle Scholar
• Palmer GC, Peeling J, Corbett D, Del Bigio MR, Hudzik TJ. T2-weighted MRI correlates with long-term histopathology, neurology scores, and skilled motor behavior in a rat stroke model. Ann. NY Acad. Sci.939, 283–296 (2001).
   PubMedGoogle Scholar
• Saver JL, Johnston KC, Homer D et al. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. Stroke30(2), 293–298 (1999).
   PubMed Web of Science ®Google Scholar
• Schaar KL, Brenneman MM, Savitz SI. Functional assessments in the rodent stroke model. Exp. Transl. Stroke Med.2(1), 13 (2010).
   PubMedGoogle Scholar
• Devries AC, Nelson RJ, Traystman RJ, Hurn PD. Cognitive and behavioral assessment in experimental stroke research: will it prove useful? Neurosci. Biobehav. Rev.25(4), 325–342 (2001).
   PubMed Web of Science ®Google Scholar
• Grabowski M, Brundin P, Johansson BB. Paw-reaching, sensorimotor, and rotational behavior after brain infarction in rats. Stroke24(6), 889–895 (1993).
   PubMed Web of Science ®Google Scholar
• Roof RL, Schielke GP, Ren X, Hall ED. A comparison of long-term functional outcome after 2 middle cerebral artery occlusion models in rats. Stroke32(11), 2648–2657 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx1(1), 36–45 (2004).
   PubMedGoogle Scholar
• Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Stroke20(12), 1627–1642 (1989).
   PubMed Web of Science ®Google Scholar
• Corbett D, Thornhill J. Temperature modulation (hypothermic and hyperthermic conditions) and its influence on histological and behavioral outcomes following cerebral ischemia. Brain Pathol.10(1), 145–152 (2000).
   PubMed Web of Science ®Google Scholar
• Buchan A, Pulsinelli WA. Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J. Neurosci.10(1), 311–316 (1990).
   PubMed Web of Science ®Google Scholar
• Hainsworth AH, Markus HS. Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J. Cereb. Blood Flow Metab.28(12), 1877–1891 (2008).
   PubMed Web of Science ®Google Scholar
• Feuerstein GZ, Zaleska MM, Krams M et al. Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J. Cereb. Blood Flow Metab.28(1), 217–219 (2008).
   PubMed Web of Science ®Google Scholar
• Minnerup J, Wersching H, Diederich K et al. Methodological quality of preclinical stroke studies is not required for publication in high-impact journals. J. Cereb. Blood Flow Metab.30(9), 1619–1624 (2010).
   PubMedGoogle Scholar
• Schmitz J, Roos C, Zischler H. Primate phylogeny: molecular evidence from retroposons. Cytogenet. Genome Res.108(1–3), 26–37 (2005).
   PubMedGoogle Scholar
• Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN, Wood A. The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology56(2), 329–341 (2009).
   PubMedGoogle Scholar
• Murphy SJ, Mccullough LD, Smith JM. Stroke in the female: role of biological sex and estrogen. ILAR J.45(2), 147–159 (2004).
   PubMedGoogle Scholar
• Graham SM, Mccullough LD, Murphy SJ. Animal models of ischemic stroke: balancing experimental aims and animal care. Comp. Med.54(5), 486–496 (2004).
   PubMed Web of Science ®Google Scholar
• Nehls DG, Cartwright M, Spetzler RF. Experimental primate stroke model. Neurosurgery18(3), 388–389 (1986).
   PubMedGoogle Scholar
• Spetzler RF, Zabramski JM, Kaufman B, Yeung HN. Acute NMR changes during MCA occlusion: a preliminary study in primates. Stroke14(2), 185–191 (1983).
   PubMedGoogle Scholar
• Mack WJ, Komotar RJ, Mocco J et al. Serial magnetic resonance imaging in experimental primate stroke: validation of MRI for pre-clinical cerebroprotective trials. Neurol. Res.25(8), 846–852 (2003).
   PubMed Web of Science ®Google Scholar
• Huang J, Mocco J, Choudhri TF et al. A modified transorbital baboon model of reperfused stroke. Stroke31(12), 3054–3063 (2000).
   PubMed Web of Science ®Google Scholar
• D’ambrosio AL, Sughrue ME, Mocco J et al. A modified transorbital baboon model of reperfused stroke. Methods Enzymol.386, 60–73 (2004).
   PubMedGoogle Scholar
• Del Zoppo GJ, Copeland BR, Harker LA et al. Experimental acute thrombotic stroke in baboons. Stroke17(6), 1254–1265 (1986).
   PubMed Web of Science ®Google Scholar
• Mack WJ, King RG, Hoh DJ et al. An improved functional neurological examination for use in nonhuman primate studies of focal reperfused cerebral ischemia. Neurol. Res.25(3), 280–284 (2003).
   PubMed Web of Science ®Google Scholar
• Del Zoppo GJ, Copeland BR, Waltz TA, Zyroff J, Plow EF, Harker LA. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke17(4), 638–643 (1986).
   PubMed Web of Science ®Google Scholar
• Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke36(10), 2311–2320 (2005).
   PubMed Web of Science ®Google Scholar
• Mocco J, Mack WJ, Ducruet AF et al. Preclinical evaluation of the neuroprotective effect of soluble complement receptor type 1 in a nonhuman primate model of reperfused stroke. J. Neurosurg.105(4), 595–601 (2006).
   PubMed Web of Science ®Google Scholar
• Ducruet AF, Mocco J, Mack WJ et al. Pre-clinical evaluation of an sLe x-glycosylated complement inhibitory protein in a non-human primate model of reperfused stroke. J. Med. Primatol.36(6), 375–380 (2007).
   PubMedGoogle Scholar
• Mocco J, Choudhri T, Huang J et al. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ. Res.91(10), 907–914 (2002).
   PubMed Web of Science ®Google Scholar
• De Crespigny AJ, D’arceuil HE, Maynard KI et al. Acute studies of a new primate model of reversible middle cerebral artery occlusion. J. Stroke Cerebrovasc. Dis.14(2), 80–87 (2005).
   PubMedGoogle Scholar
• Roitberg B, Khan N, Tuccar E et al. Chronic ischemic stroke model in cynomolgus monkeys: behavioral, neuroimaging and anatomical study. Neurol. Res.25(1), 68–78 (2003).
   PubMed Web of Science ®Google Scholar
• Murphy SJ, Kirsch JR, Zhang W et al. Can gender differences be evaluated in a rhesus macaque (Macaca mulatta) model of focal cerebral ischemia? Comp. Med.58(6), 588–596 (2008).
   PubMedGoogle Scholar
• Takamatsu H, Tsukada H, Kakiuchi T, Nishiyama S, Noda A, Umemura K. Detection of reperfusion injury using PET in a monkey model of cerebral ischemia. J. Nucl. Med.41(8), 1409–1416 (2000).
   PubMed Web of Science ®Google Scholar
• West GA, Golshani KJ, Doyle KP et al. A new model of cortical stroke in the rhesus macaque. J. Cereb. Blood Flow Metab.29(6), 1175–1186 (2009).
   PubMedGoogle Scholar
• Hirouchi Y, Suzuki E, Mitsuoka C et al. Neuroimaging and histopathological evaluation of delayed neurological damage produced by artificial occlusion of the middle cerebral artery in cynomolgus monkeys: establishment of a monkey model for delayed cerebral ischemia. Exp. Toxicol. Pathol.59(1), 9–16 (2007).
   PubMedGoogle Scholar
• Maeda M, Takamatsu H, Furuichi Y et al. Characterization of a novel thrombotic middle cerebral artery occlusion model in monkeys that exhibits progressive hypoperfusion and robust cortical infarction. J. Neurosci. Methods146(1), 106–115 (2005).
   PubMed Web of Science ®Google Scholar
• Susumu T, Yoshikawa T, Akiyoshi Y, Nagata R, Fujiwara M, Kito G. Effects of intra-arterial urokinase on a non-human primate thromboembolic stroke model. J. Pharmacol. Sci.100(4), 278–284 (2006).
   PubMedGoogle Scholar
• Furuichi Y, Katsuta K, Maeda M et al. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res.965(1–2), 137–145 (2003).
   PubMed Web of Science ®Google Scholar
• Furuichi Y, Maeda M, Matsuoka N, Mutoh S, Yanagihara T. Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator. Exp. Neurol.204(1), 138–146 (2007).
   PubMedGoogle Scholar
• Takamatsu H, Tsukada H, Noda A et al. FK506 attenuates early ischemic neuronal death in a monkey model of stroke. J. Nucl. Med.42(12), 1833–1840 (2001).
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Akiyoshi Y, Susumu T et al. Ginsenoside Rb1 reduces neurodegeneration in the peri-infarct area of a thromboembolic stroke model in non-human primates. J. Pharmacol. Sci.107(1), 32–40 (2008).
   PubMedGoogle Scholar
• Li HL, Yan C, Li J et al. Seroprevalence of Toxoplasma gondii in bred cynomolgus monkeys (Macaca fascicularis) in China. J. Parasitol.96(4), 807–808 (2010).
   PubMedGoogle Scholar
• Kawaguchi AT, Haida M, Yamano M, Fukumoto D, Ogata Y, Tsukada H. Liposome-encapsulated hemoglobin ameliorates ischemic stroke in nonhuman primates: an acute study. J. Pharmacol. Exp. Ther.332(2), 429–436 (2010).
   PubMed Web of Science ®Google Scholar
• Zerhouni EA. Translational research: moving discovery to practice. Clin. Pharmacol. Ther.81(1), 126–128 (2007).
   PubMedGoogle Scholar
• Woolf SH. The meaning of translational research and why it matters. JAMA299(2), 211–213 (2008).
   PubMed Web of Science ®Google Scholar
• Mandava P, Kalkonde YV, Rochat RH, Kent TA. A matching algorithm to address imbalances in study populations: application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator Acute Stroke Trial. Stroke41(4), 765–770 (2010).
   PubMedGoogle Scholar
• Uyttenboogaart M, Stewart RE, Vroomen PC, De Keyser J, Luijckx GJ. Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke36(9), 1984–1987 (2005).
   PubMed Web of Science ®Google Scholar
• Muir KW. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke33(6), 1545–1550 (2002).
   PubMed Web of Science ®Google Scholar
• Crossley NA, Sena E, Goehler J et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke39(3), 929–934 (2008).
   PubMed Web of Science ®Google Scholar
• Johnston K. What are surrogate outcome measures and why do they fail in clinical research? Neuroepidemiology18(4), 167–173 (1999).
   PubMed Web of Science ®Google Scholar
• Hoehn-Berlage M, Eis M, Back T, Kohno K, Yamashita K. Changes of relaxation times (T1, T2) and apparent diffusion coefficient after permanent middle cerebral artery occlusion in the rat: temporal evolution, regional extent, and comparison with histology. Magn. Reson. Med.34(6), 824–834 (1995).
   PubMed Web of Science ®Google Scholar
• Jokivarsi KT, Hiltunen Y, Tuunanen PI, Kauppinen RA, Grohn OH. Correlating tissue outcome with quantitative multiparametric MRI of acute cerebral ischemia in rats. J. Cereb. Blood Flow Metab.30(2), 415–427 (2010).
   PubMedGoogle Scholar
• Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke17(6), 1304–1308 (1986).
   PubMed Web of Science ®Google Scholar
• Murakami Y, Takamatsu H, Noda A et al. Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. J. Nucl. Med.45(11), 1946–1949 (2004).
   PubMedGoogle Scholar
• Yanagihara T. Experimental stroke in gerbils: effect on translation and transcription. Brain Res.158(2), 435–444 (1978).
   PubMedGoogle Scholar
• Kharlamov A, Laverde GC, Nemoto EM et al. MAP2 immunostaining in thick sections for early ischemic stroke infarct volume in non-human primate brain. J. Neurosci. Methods182(2), 205–210 (2009).
   PubMedGoogle Scholar
• Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia – the ischemic penumbra. Stroke12(6), 723–725 (1981).
   PubMed Web of Science ®Google Scholar
• Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab. Dispos.32(6), 612–619 (2004).
   PubMed Web of Science ®Google Scholar
• Nudo RJ, Larson D, Plautz EJ, Friel KM, Barbay S, Frost SB. A squirrel monkey model of poststroke motor recovery. ILAR J.44(2), 161–174 (2003).
   PubMed Web of Science ®Google Scholar
• Yonas H, Wolfson SK Jr, Dujovny M, Boehnke M, Cook E. Selective lenticulostriate occlusion in the primate. A highly focal cerebral ischemia model. Stroke12(5), 567–572 (1981).
   PubMed Web of Science ®Google Scholar
• Hamberg LM, Hunter GJ, Maynard KI et al. Functional CT perfusion imaging in predicting the extent of cerebral infarction from a 3-hour middle cerebral arterial occlusion in a primate stroke model. AJNR Am. J. Neuroradiol.23(6), 1013–1021 (2002).
   PubMed Web of Science ®Google Scholar
• D’arceuil HE, Duggan M, He J, Pryor J, De Crespigny A. Middle cerebral artery occlusion in Macaca fascicularis: acute and chronic stroke evolution. J. Med. Primatol.35(2), 78–86 (2006).
   PubMedGoogle Scholar
• Kito G, Nishimura A, Susumu T et al. Experimental thromboembolic stroke in cynomolgus monkey. J. Neurosci. Methods105(1), 45–53 (2001).
   PubMed Web of Science ®Google Scholar
• Kuge Y, Yokota C, Tagaya M et al. Serial changes in cerebral blood flow and flow-metabolism uncoupling in primates with acute thromboembolic stroke. J. Cereb. Blood Flow Metab.21(3), 202–210 (2001).
   PubMedGoogle Scholar
• Qureshi AI, Suri MF, Ali Z et al. Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a non-human primate model. Neuroradiology47(11), 845–854 (2005).
   PubMed Web of Science ®Google Scholar
• Sughrue ME, Mocco J, Mack WJ et al. Bioethical considerations in translational research: primate stroke. Am. J. Bioeth.9(5), 3–12 (2009).
   PubMed Web of Science ®Google Scholar
• Dorman PJ, Sandercock PA. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Stroke27(9), 1507–1515 (1996).
   PubMed Web of Science ®Google Scholar
• Fuster JM. Unit activity in prefrontal cortex during delayed-response performance: neuronal correlates of transient memory. J. Neurophysiol.36(1), 61–78 (1973).
   PubMed Web of Science ®Google Scholar
• Zola-Morgan S, Squire LR. Preserved learning in monkeys with medial temporal lesions: sparing of motor and cognitive skills. J. Neurosci.4(4), 1072–1085 (1984).
   PubMed Web of Science ®Google Scholar
• Palfi S, Conde F, Riche D et al. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat. Med.4(8), 963–966 (1998).
   PubMed Web of Science ®Google Scholar
• Herndon JG, Moss MB, Rosene DL, Killiany RJ. Patterns of cognitive decline in aged rhesus monkeys. Behav. Brain Res.87(1), 25–34 (1997).
   PubMed Web of Science ®Google Scholar
• Moore TL, Killiany RJ, Herndon JG, Rosene DL, Moss MB. Impairment in abstraction and set shifting in aged rhesus monkeys. Neurobiol. Aging24(1), 125–134 (2003).
   PubMedGoogle Scholar
• Moss MB, Jonak E. Cerebrovascular disease and dementia: a primate model of hypertension and cognition. Alzheimers Dement.3(Suppl. 2), S6–S15 (2007).
   Google Scholar
• Rother J. Neuroprotection does not work! Stroke39(2), 523–524 (2008).
   PubMed Web of Science ®Google Scholar
• Macleod MR, Fisher M, O’collins V et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke40(3), e50–e52 (2009).
   PubMed Web of Science ®Google Scholar
• Zivin JA. Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA). Ann. Neurol.66(1), 6–10 (2009).
   PubMed Web of Science ®Google Scholar
• Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke40(7), 2438–2441 (2009).
   PubMed Web of Science ®Google Scholar
• Symon L, Crockard HA, Dorsch NW, Branston NM, Juhasz J. Local cerebral blood flow and vascular reactivity in a chronic stable stroke in baboons. Stroke6(5), 482–492 (1975).
   PubMed Web of Science ®Google Scholar
• Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke8(1), 51–57 (1977).
   PubMed Web of Science ®Google Scholar
• Kakuda W, Lansberg MG, Thijs VN et al. Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients. J. Cereb. Blood Flow Metab.28(5), 887–891 (2008).
   PubMedGoogle Scholar
• Olivot JM, Mlynash M, Thijs VN et al. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke39(8), 2257–2263 (2008).
   PubMed Web of Science ®Google Scholar
• Nagakane Y, Christensen S, Brekenfeld C et al. EPITHET: positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke42(1), 59–64 (2010).
   PubMedGoogle Scholar
• Kakuda W, Hamilton S, Thijs VN et al. Optimal outcome measures for detecting clinical benefits of early reperfusion: insights from the DEFUSE Study. J. Stroke Cerebrovasc. Dis.17(4), 235–240 (2008).
   PubMedGoogle Scholar
• Goldberg MP, Ransom BR. New light on white matter. Stroke34(2), 330–332 (2003).
   PubMed Web of Science ®Google Scholar
• Arakawa S, Wright PM, Koga M et al. Ischemic thresholds for gray and white matter: a diffusion and perfusion magnetic resonance study. Stroke37(5), 1211–1216 (2006).
   PubMedGoogle Scholar
• Hoyte L, Barber PA, Buchan AM, Hill MD. The rise and fall of NMDA antagonists for ischemic stroke. Curr. Mol. Med.4(2), 131–136 (2004).
   PubMed Web of Science ®Google Scholar
• Koga M, Reutens DC, Wright P et al. The existence and evolution of diffusion-perfusion mismatched tissue in white and gray matter after acute stroke. Stroke36(10), 2132–2137 (2005).
   PubMed Web of Science ®Google Scholar
• Dewar D, Yam P, Mcculloch J. Drug development for stroke: importance of protecting cerebral white matter. Eur. J. Pharmacol.375(1–3), 41–50 (1999).
   PubMedGoogle Scholar
• Micu I, Jiang Q, Coderre E et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature439(7079), 988–992 (2006).
   PubMed Web of Science ®Google Scholar
• Tang XN, Liu L, Yenari MA. Combination therapy with hypothermia for treatment of cerebral ischemia. J. Neurotrauma26(3), 325–331 (2009).
   PubMed Web of Science ®Google Scholar
• Schmid-Elsaesser R, Hungerhuber E, Zausinger S, Baethmann A, Reulen HJ. Combination drug therapy and mild hypothermia: a promising treatment strategy for reversible, focal cerebral ischemia. Stroke30(9), 1891–1899 (1999).
   PubMed Web of Science ®Google Scholar
• Fagan SC, Bowes MP, Berri SA, Zivin JA. Combination treatment for acute ischemic stroke: a ray of hope? J. Stroke Cerebrovasc. Dis.8(6), 359–367 (1999).
   PubMedGoogle Scholar
• Martin-Schild S, Hallevi H, Shaltoni H et al. Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermia. J. Stroke Cerebrovasc. Dis.18(2), 86–96 (2009).
   PubMedGoogle Scholar